BioScrip (BIOS) Misses Q3 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
BioScrip Reports Third Quarter 2015 Financial Results
November 4, 2015 7:00 AM ESTConsolidated Adjusted EBITDA of $6.2 Million
Results Demonstrate Progress Against Financial Improvement Plan
Reaffirms 2016 Adjusted EBITDA Guidance of Between $50 Million - $60 Million
ELMSFORD, N.Y.--(BUSINESS WIRE)-- BioScrip, Inc. (NASDAQ: BIOS) (the Company) today announced 2015 third quarter financial results.
Third Quarter Highlights
Consolidated Adjusted EBITDA was $6.2 million, primarily due to the early positive contributions of BioScrips previously announced plan to reduce costs and focus on its core infusion business; Revenue... More